OGD2 PHARMA

OGD2 Pharma is a privately held biotechnology company based in Nantes, France, founded in 2014. The company focuses on the discovery and development of innovative cancer immunotherapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2), a tumor-specific antigen expressed on several types of pediatric and adult cancers.